Results-NGF concentrations were significantly higher in children with systemic [254 (SD 256.1) pg ml-'; P < 0.001], polyarticular [165.2 (300.8) pg ml-'; P < 0.05], and pauciarticular [106.8 (111.8) pg ml-'; P < 0.005] onset juvenile chronic arthritis than in controls. In all subsets, NGF concentrations were higher in the active than in the inactive phase of the disease. A significant direct correlation between NGF concentrations and erythrocyte sedimentation rate was found both in the systemic and in the polyarticular onset juvenile chronic arthritis. Conclusions-The increase in NGF concentrations in all juvenile chronic arthritis subsets and the correlation with disease activity suggest that NGF may take an active part in joint inflammation.
(Ann Rheum Dis 1996;55: [745] [746] [747] [748] Nerve growth factor (NGF) is a neurotrophic protein responsible for the development and differentiation of sympathetic, sensory, and cholinergic neurones.' In the peripheral nervous system, NGF is involved in the modulation of the function of the nerve terminals, controlling their development, survival, and production and release of neurotransmitters.' NGF is produced by different cells, such as keratinocytes, smooth muscle cells, fibroblasts, and lymphocytes.' NGF has been shown to increase the chemotaxis of polymorphonuclear cells, the B cell production of immunoglobulins, and the T cell dependent production of autoantibodies.' NGF interacts specifically with nociceptive sensory neurones, by increasing the content of neuropeptides, in particular substance P.' The release of neuropeptides from nerve terminals elicits a local flare called neurogenic inflammation4 mainly linked to the release of substance P which is involved in the activation of synoviocytes and cartilage breakdown in arthritis (for review see Matucci-Cerinic, 1993'). The presence ofNGF is essential in the production and in particular the release of neuropeptides induced by different stimuli. 6 This evidence suggests that the presence of NGF is associated with the maintenance of neurogenic inflammation. 4 Systemic juvenile chronic arthritis was defined active in presence of all the following variables: spiking fever > 38.5'C; typical rash; joint swelling with reduced range of motion in one or more joints; Hb < 10 g dl-1; 5. ESR > 25 mm h-1.
Polyarticular arthritis was defined active in the presence of: (1) ESR > 25 mm h-'; (2) swelling with reduced range of motion in more than five joints. Pauciarticular arthritis was defined active in presence of joint swelling with reduced range of motion in one to four joints.
The basic treatment in children with systemic juvenile chronic arthritis consisted of steroids and non-steroidal anti-inflammatory drugs (NSAID), while in polyarticular subset, methotrexate represented the second line drug used in association with NSAID. All patients in the pauciarticular onset group were given only NSAID. Forty healthy children (25 girls, 15 boys; mean age 6 years, 7 months) matched for sex and age were chosen as controls.
Disease activity was scored following a previous scoring system modified by us'5: 0 = no activity; systemic subset 1 = fever < 38°C, mild joint swelling, ESR 25-40 mm h-', Hb antibody against NGF, diluted 1:100 in PBS, were added to each well. After incubation for 4 h at 20'C, the plates were washed and incubated with biotinylated rat immunoglobulins (1:8000, Zymed). The subsequent incubation with peroxidase conjugated streptavidin (Zymed) and addition of ortophenyldiamine resulted in a colorimetric reaction the optical density of which was measured at 490 nm using a Dynatech MR 5000 microplate reader. Specificity for NGF was also assessed using a recombinant human NGF.71' Recombinant brain derived neurotrophic factor is not recognised in the ELISA at concentrations up to 20 ng ml-'. Serum NGF was correlated with disease activity and haematological variables (that is, ESR and C reactive protein).
STATISTICAL ANALYSIS
Evaluation of the differences in NGF levels observed between the three groups of juvenile chronic arthritis and controls was performed with the unpaired Student t test. The significance of the differences was also confirmed by the parameter-free MannWhitney U test. The correlation between NGF and ESR, C reactive protein, and IgG, in both active and inactive disease, was tested by Pearson's correlation coefficient.
Results
Of the 80 children studied, 53 were in the active phase of the disease and 27 in the inactive phase. The mean NGF value in healthy children was 6 (SD 4.5) pg ml-'. The Correlation of NGF with the different grade of disease activity in each subset showed that NGF concentrations rise progressively in parallel with the increase in disease activity ( fig  1) . The increase was more significant when the disease reached activity grades 2 and 3.
NGF concentrations were also determined in synovial fluid from two children with active pauciarticular juvenile chronic arthritis (376 and 309 pg ml-'; serum concentrations were 155 and 158 pg ml-') respectively.
Discussion
Our data show a striking rise in circulating NGF in juvenile chronic arthritis. The highest values are detected in systemic onset juvenile chronic arthritis, but in the other two subsets the values are higher than in controls. NGF concentrations are increased in the active Lymphocyte Figure 2 The possible sources of nerve growth factor (NGF) are shown. It is noteworthy that NGF may act in an autocrine and paracrine way. It may be released by nerve terminals and influence the immune and synovial systems, as well as being released by those two systems, which influence each other and the nervous system. phase of each subset and remain raised in the inactive phase indicating also that if disease activity is decreasing the serum NGF is kept at a higher level by mechanism still to be determined. NGF concentrations are also high in the pauciarticular subset of juvenile chronic arthritis, where the inflammatory process is limited to one or few joints and systemic involvement is usually lacking.
The source of the increased circulating concentrations of NGF is still a matter of debate (fig 2) . The local increase may be derived from synoviocyte proliferation or lymphocytes or peripheral nervous terminals activation in inflamed joints, or a combination of all these. Some pathogenic events (for example, local production of TNF-a and interleukin 1) may trigger the significant increase of NGF in synovial fluid and in the systemic circulation. Cytokines such as interleukin 1, interleukin 6, and TNF-a play an important role in the pathogenesis of juvenile chronic arthritis.5 1718 These cytokines have been shown to stimulate NGF synthesis by the peripheral nervous system during chronic inflammatory processes. ' NGF induces the synthesis and the release from sensory endings of substance P, which is mainly related to neurogenic inflammation. 3 4 The presence of NGF is considered to be the main switch to activate the release of neuropeptides from C fibres and generate neurogenic inflammation.6 In this perspective, the increased concentrations of NGF, either in the circulation or in synovial fluid, might amplify the inflammatory joint process by facilitating the development of neurogenic inflammation.
It is interesting to stress that NGF concentrations are directly correlated to ESR and in particular to the progressive increase in disease activity. This kind of behaviour is similar to that observed in multiple sclerosis, where NGF increases during acute attacks and diminishes during remission.7 In SLE, increased NGF concentrations have been found concomitantly with disease relapses. 8 Our data clearly show that NGF concentrations are increased in all juvenile chronic arthritis subsets and are correlated with disease activity. This evidence seems to strengthen the hypothesis that NGF is involved-primarily or secondarily-in inflammation, though it is still unknown whether it plays an active role or is just the result of a defence mechanism in the pathogenesis of juvenile chronic arthritis. Further investigations are needed to determine the source of circulating NGF, to discover whether NGF is a marker of disease activity, and to identify its real significance in the evolution of the disease. 
